Iterion Therapeutics Announces Results from Preclinical study of Tegavivint
Iterion shares results from collaboration with Cancer Research UK (CRUK)
The Small Molecule BC-2059 Inhibits Wingless/Integrated (Wnt) – Dependent Gene Transcription in Cancer through Disruption of the Transducin B-Like 1-B-Catenin Protein Complex
Raffaella Soldi, Tithi Ghosh Halder, Samuel Sampson, Hariprasad Vankayalapati, Alexis Weston, Trason Thode, Kapil N Bhalla, Serina NG, Ryan Rodrigues Del Villar, Kevin Drenner, Mohan R Kaadige, Stephen K Horrigan, Surinder K Batra, Ravi Salgia, Sunil Sharma
Iterion Therapeutics Announces Results from Phase 1 Dose Escalation Study of Tegavivint in Desmoid Tumors to be Presented at the 2022 ASCO Annual Meeting
Results announced from dose escalation study of tegavivint in desmoid tumors.
Iterion Therapeutics Announces Three Posters To Be Presented at AACR 2022
Iterion Therapeutics announces presentation of three posters involving research into tegavivint at the AACR 2022 Annual Meeting
Iterion Announces Initiation of Phase 1 Clinical Trial to Study Tegavivint in Combination with Osimertinib in Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer
Iterion initiates Phase 1 clinical trial to investigate tegavivint in a first-line combination study with osimertinib in previously untreated patients with metastatic epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer.
Iterion Therapeutics Announces Initiation of Phase 1/2 Clinical Trial to Study Tegavivint in Pediatric Cancers
Children’s Oncology Group Pediatric Early Phase Clinical Trials Network, a National Cancer Institute-supported clinical trials group, sponsors first clinical study for tegavivint in the pediatric population
Iterion Therapeutics Announces Phase 1 Clinical Trial to Study in Acute Myeloid Leukemia
Iterion Therapeutics announces phase 1 clinical trial.
Iterion welcomes new Chief Operating Officer, Jean Chang
Iterion Therapeutics hires Jean Chang as Chief Operating Officer.
Iterion Therapeutics Confirms Safety of Tegavivint Following Completion of Enrollment in Phase 1/2a Expansion Study in Patients with Desmoid Tumors
Iterion Therapeutics confirms safety of tegavivint following completion of enrollment in phase 1/2a expansion study.